A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly
| Autor: | I. Fusco, S. Stefanacci, Luigi Rigacci, S. Di Lollo, G. Bellesi, F. Innocenti, Franco Bernardi, P. Rossi Ferrini, Giovanni Longo, Renato Alterini |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Cyclophosphamide Gastrointestinal Diseases medicine.medical_treatment Neutropenia Gastroenterology Disease-Free Survival Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Life Tables Etoposide Aged Mitoxantrone Chemotherapy business.industry Lymphoma Non-Hodgkin Remission Induction Hematology medicine.disease Hematologic Diseases Survival Analysis Lymphoma Surgery Non-Hodgkin's lymphoma Treatment Outcome Oncology Feasibility Studies Female business medicine.drug |
| Zdroj: | Leukemialymphoma. 20(5-6) |
| ISSN: | 1042-8194 |
| Popis: | Age has proved to be an important prognostic factor in patients with advanced non-Hodgkin lymphoma (NHL) and these patients require intensive and extensive therapy. Dose-reduction and therapy attenuation have reduced treatment-related toxicity, but have also decreased therapeutic efficacy. Between January 1990 and December 1992, 41 previously untreated patients, 65 years with stage 2-4 intermediate- or high-grade NHL were treated with a new therapeutic scheme which included Mitoxantrone, Etoposide, Cyclophosphamide and Prednisone (MiCEP). Twenty-eight patients achieved a complete remission, ten patients partial remission (overall response rate of 93%) and two cases were resistant. The overall survival was 66% with a median follow-up of 24 months from diagnosis: three patients relapsed after a median period of 7 months. The relapse-free survival was 92% after a median follow-up of 18 months. Blood and other organ toxicity was acceptable and 12% of patients experienced a grade 4 (WHO) neutropenia. In conclusion, MiCEP was effective in inducing a good remission rate with moderate toxic effects in elderly patients with intermediate- or high-grade NHL and appears to be a useful combination to use in this group of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|